Sodium hydrosulfide prevents myocardial dysfunction through modulation of extracellular matrix accumulation and vascular density

International Journal of Molecular Sciences

Volumn 15, Issue 12, 2014, Pages 23212-23226

  Pan, Li Long ^a   Wang, Xian Li ^a   Wang, Xi Ling ^a   Zhu, Yi Zhun ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Cardioprotection; Hydrogen sulfide; Infarction; Neovascularization; Remodeling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD34 ANTIBODY; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYSTATHIONINE GAMMA LYASE; HEME OXYGENASE 1; HYDROGEN SULFIDE; MATRIX METALLOPROTEINASE; SODIUM HYDROGEN SULFIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; ACTIN; COLLAGEN TYPE 2; GELATINASE B; MMP9 PROTEIN, RAT; SODIUM BISULFIDE; SULFIDE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; FLUORESCENCE MICROSCOPY; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART RATE; HEART VENTRICLE REMODELING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; MYOCARDIAL DISEASE; NONHUMAN; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; ANGIOGENESIS; ANIMAL; DRUG EFFECTS; FIBROSIS; GENETICS; METABOLISM; MYOCARDIAL INFARCTION; PATHOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ACTINS; ANIMALS; COLLAGEN TYPE II; COLLAGEN TYPE III; CYSTATHIONINE GAMMA-LYASE; EXTRACELLULAR MATRIX; FIBROSIS; HEME OXYGENASE-1; MALE; MATRIX METALLOPROTEINASE 9; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; SULFIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR REMODELING;

EID: 84917706957     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151223212     Document Type: Article

References (42)

1. Inglis, S. C.; Bebchuk, J.; Al-Suhaim, S. A.; Case, J.; Pfeffer, M. A.; Solomon, S. D.; Hou, Y. R.; Pitt, B.; Dargie, H. J.; Ford, I.; et al. Peripheral artery disease and outcomes after myocardial infarction: An individual-patient meta-analysis of 28, 771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. Int. J. Cardiol. 2013, 168, 1094-1101.
2. Golomb, B. A.; Dang, T. T.; Criqui, M. H. Peripheral arterial disease: Morbidity and mortality implications. Circulation 2006, 114, 688-699.
3. Halade, G. V.; Jin, Y. F.; Lindsey, M. L. Matrix metalloproteinase (MMP)-9: A proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol. Ther. 2013, 139, 32-40.
4. Saparov, A.; Chen, C. W.; Beckman, S. A.; Wang, Y.; Huard, J. The role of antioxidation and immunomodulation in postnatal multipotent stem cell-mediated cardiac repair. Int. J. Mol. Sci. 2013, 14, 16258-16279.
5. Konstam, M. A.; Kramer, D. G.; Patel, A. R.; Maron, M. S.; Udelson, J. E. Left ventricular remodeling in heart failure: Current concepts in clinical significance and assessment. JACC Cardiovasc. Imaging 2011, 4, 98-108.
6. Pan, L. L.; Liu, X. H.; Shen, Y. Q.; Wang, N. Z.; Xu, J.; Wu, D.; Xiong, Q. H.; Deng, H. Y.; Huang, G. Y.; Zhu, Y. Z. Inhibition of NADPH oxidase 4-related signaling by sodium hydrosulfide attenuates myocardial fibrotic response. Int. J. Cardiol. 2013, 168, 3770-3778.
7. Spinale, F. G.; Villarreal, F. Targeting matrix metalloproteinases in heart disease: Lessons from endogenous inhibitors. Biochem. Pharmacol. 2014, 90, 7-15.
8. Pan, L. L.; Liu, X. H.; Gong, Q. H.; Yang, H. B.; Zhu, Y. Z. Role of cystathionine γ-lyase/hydrogen sulfide pathway in cardiovascular disease: A novel therapeutic strategy? Antioxid. Redox Signal. 2012, 17, 106-118.
9. Zhu, Y. Z.; Wang, Z. J.; Ho, P.; Loke, Y. Y.; Zhu, Y. C.; Huang, S. H.; Tan, C. S.; Whiteman, M.; Lu, J.; Moore, P. K. Hydrogen sulfide and its possible roles in myocardial ischemia in experimental rats. J. Appl. Physiol. 2007, 102, 261-268.
10. Wang, Y.; Zhao, X.; Jin, H.; Wei, H.; Li, W.; Bu, D.; Tang, X.; Ren, Y.; Tang, C.; Du, J. Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 173-179.
11. Zhao, W.; Zhang, J.; Lu, Y.; Wang, R. The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener. EMBO J. 2001, 20, 6008-6016.
12. Szabo, C. Hydrogen sulphide and its therapeutic potential. Nat. Rev. Drug Discov. 2007, 6, 917-935.
13. Hibuya, N.; Koike, S.; Tanaka, M.; Ishigami-Yuasa, M.; Kimura, Y.; Ogasawara, Y.; Fukui, K.; Nagahara, N.; Kimura, H. A novel pathway for the production of hydrogen sulfide from D-cysteine in mammalian cells. Nat. Commun. 2013, 4, 1366.
14. Kimura, H. Signaling molecules: Hydrogen sulfide and polysulfide. Antioxid. Redox Signal. 2014, doi: 10. 1089/ars. 2014. 5869.
15. Polhemus, D. J.; Kondo, K.; Bhushan, S.; Bir, S. C.; Kevil, C. G.; Murohara, T.; Lefer, D. J.; Calvert, J. W. Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis. Circ. Heart Fail. 2013, 6, 1077-1086.
16. Snijder, P. M.; Frenay, A. S.; de Boer, R. A.; Pasch, A.; Hillebrands, J.; Leuvenink, H. G.; van Goor, H. Exogenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates Angiotensin II-induced hypertensive heart disease in rats. Br. J. Pharmacol. 2014, doi: 10. 1111/bph. 12825.
17. Polhemus, D. J.; Lefer, D. J. Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease. Circ. Res. 2014, 114, 730-737.
18. Shen, Y.; Guo, W.; Wang, Z.; Zhang, Y.; Zhong, L.; Zhu, Y. Protective effects of hydrogen sulfide in hypoxic human umbilical vein endothelial cells: A possible mitochondria-dependent pathway. Int. J. Mol. Sci. 2013, 14, 13093-13108.
19. Pan, L. L.; Liu, X. H.; Gong, Q. H.; Wu, D.; Zhu, Y. Z. Hydrogen sulfide attenuated tumor necrosis factor-α-induced inflammatory signaling and dysfunction in vascular endothelial cells. PLoS One 2011, 6, e19766.
20. Mustafa, A. K.; Sikka, G.; Gazi, S. K.; Steppan, J.; Jung, S. M.; Bhunia, A. K.; Barodka, V. M.; Gazi, F. K.; Barrow, R. K.; Wang, R.; et al. Hydrogen sulfide as endothelium-derived hyperpolarizing factor sulfhydrates potassium channels. Circ. Res. 2011, 109, 1259-1268.
21. Wang, X.; Wang, Q.; Guo, W.; Zhu, Y. Z. Hydrogen sulfide attenuates cardiac dysfunction in a rat model of heart failure: A mechanism through cardiac mitochondrial protection. Biosci. Rep. 2011, 31, 87-98.
22. Liu, X. H.; Pan, L. L.; Deng, H. Y.; Xiong, Q. H.; Wu, D.; Huang, G.; Gong, Q. H.; Zhu, Y. Z. Leonurine (SCM-198) attenuates myocardial fibrotic response via inhibition of NADPH oxidase 4. Free Radic. Biol. Med. 2013, 54, 93-104.
23. Dobaczewski, M.; Gonzalez-Quesada, C.; Frangogiannis, N. G. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J. Mol. Cell. Cardiol. 2010, 48, 504-511.
24. Kondo, K.; Bhushan, S.; King, A. L.; Prabhu, S. D.; Hamid, T.; Koenig, S.; Murohara, T.; Predmore, B. L.; Gojon, G., Sr.; Gojon, G., Jr.; et al. H2S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase. Circulation 2013, 127, 1116-1127.
25. Wang, Q.; Liu, H. R.; Mu, Q.; Rose, P.; Zhu, Y. Z. S-propargyl-cysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: The contribution of the hydrogen sulfide-mediated pathway. J. Cardiovasc. Pharmacol. 2009, 54, 139-146.
26. Shen, Y.; Shen, Z.; Miao, L.; Xin, X.; Lin, S.; Zhu, Y.; Guo, W.; Zhu, Y. Z. miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-γ-lyase expression. Antioxid. Redox Signal. 2014, doi: 10. 1089/ars. 2014. 5909.
27. Calvert, J. W.; Jha, S.; Gundewar, S.; Elrod, J. W.; Ramachandran, A.; Pattillo, C. B.; Kevil, C. G.; Lefer, D. J. Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ. Res. 2009, 105, 365-374.
28. Kovacic, D.; Glavnik, N.; Marinsek, M.; Zagozen, P.; Rovan, K.; Goslar, T.; Mars, T.; Podbregar, M. Total plasma sulfide in congestive heart failure. J. Card. Fail. 2012, 18, 541-548.
29. Burchfield, J. S.; Xie, M.; Hill, J. A. Pathological ventricular remodeling Mechanisms: Part 1 of 2. Circulation 2013, 128, 388-400.
30. Heusch, G.; Libby, P.; Gersh, B.; Yellon, D.; Bohm, M.; Lopaschuk, G.; Opie, L. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 2014, 383, 1933-1943.
31. Ramirez, T. A.; Iyer, R. P.; Ghasemi, O.; Lopez, E. F.; Levin, D. B.; Zhang, J.; Zamilpa, R.; Chou, Y. M.; Jin, Y. F.; Lindsey, M. L. Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects. J. Mol. Cell. Cardiol. 2014, 72, 326-335.
32. Shinde, A. V.; Frangogiannis, N. G. Fibroblasts in myocardial infarction: A role in inflammation and repair. J. Mol. Cell. Cardiol. 2014, 70, 74-82.
33. Cai, W. J.; Wang, M. J.; Moore, P. K.; Jin, H. M.; Yao, T.; Zhu, Y. C. The novel proangiogenic effect of hydrogen sulfide is dependent on Akt phosphorylation. Cardiovasc. Res. 2007, 76, 29-40.
34. Kan, J.; Guo, W.; Huang, C.; Bao, G.; Zhu, Y.; Zhu, Y. Z., S-propargyl-cysteine, a novel water-soluble modulator of endogenous hydrogen sulfide, promotes angiogenesis through activation of signal transducer and activator of transcription 3. Antioxid. Redox Signal. 2014, 20, 2303-2316.
35. Bir, S. C.; Kolluru, G. K.; McCarthy, P.; Shen, X.; Pardue, S.; Pattillo, C. B.; Kevil, C. G. Hydrogen sulfide stimulates ischemic vascular remodeling through nitric oxide synthase and nitrite reduction activity regulating hypoxia-inducible factor-1alpha and vascular endothelial growth factor-dependent angiogenesis. J. Am. Heart Assoc. 2012, 1, e004093.
36. Sato, K.; Wu, T.; Laham, R. J.; Johnson, R. B.; Douglas, P.; Li, J.; Sellke, F. W.; Bunting, S.; Simons, M.; Post, M. J. Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. J. Am. Coll. Cardiol. 2001, 37, 616-623.
37. Chen, T. M.; Li, J.; Liu, L.; Fan, L.; Li, X. Y.; Wang, Y. T.; Abraham, N. G.; Cao, J. Effects of heme oxygenase-1 upregulation on blood pressure and cardiac function in an animal model of hypertensive myocardial infarction. Int. J. Mol. Sci. 2013, 14, 2684-2706.
38. Wang, G.; Hamid, T.; Keith, R. J.; Zhou, G.; Partridge, C. R.; Xiang, X.; Kingery, J. R.; Lewis, R. K.; Li, Q.; Rokosh, D. G.; et al. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation 2010, 121, 1912-1925.
39. Penumathsa, S. V.; Koneru, S.; Zhan, L.; John, S.; Menon, V. P.; Prasad, K.; Maulik, N. Secoisolariciresinol diglucoside induces neovascularization-mediated cardioprotection against ischemia-reperfusion injury in hypercholesterolemic myocardium. J. Mol. Cell. Cardiol. 2008, 44, 170-179.
40. Kim, Y. M.; Pae, H. O.; Park, J. E.; Lee, Y. C.; Woo, J. M.; Kim, N. H.; Choi, Y. K.; Lee, B. S.; Kim, S R.; Chung, H. T. Heme oxygenase in the regulation of vascular biology: From molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 2011, 14, 137-167.
41. Kim, J. H.; Lee, K. S.; Lee, D. K.; Kim, J.; Kwak, S. N.; Ha, K. S.; Choe, J.; Won, M. H.; Cho, B. R.; Jeoung, D.; et al. Hypoxia-responsive microRNA-101 promotes angiogenesis via heme oxygenase-1/vascular endothelial growth factor axis by targeting Cullin 3. Antioxid. Redox Signal. 2014, 21, 2469-2482.
42. Kweider, N.; Fragoulis, A.; Rosen, C.; Pecks, U.; Rath, W.; Pufe, T.; Wruck, C. J. Interplay between vascular endothelial growth factor (VEGF) and nuclear factor erythroid 2-related factor-2 (Nrf2): Implications for preeclampsia. J. Biol. Chem. 2011, 286, 42863-42872.